Diosgenin enhances 5-fluorouracil sensitivity in drug-resistant colorectal cancer cells via inhibition of ATR/Chk1-mediated DNA damage response
Cancer Treatment and Research Communications · 2026 · 49 · 101426
DOI: 10.1016/j.ctarc.2026.101426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Bita Azizzadeh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Solid Tumor Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Urmia University of Medical Sciences.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Drug resistance to 5-fluorouracil (5-FU) is one of the major challenges in the treatment of colorectal cancer, which is largely associated with the activation of DNA damage response (DDR) pathways, especially the ATR-CHK1 axis, and increased activity of drug efflux pumps. The aim of this study was to investigate the effect of diosgenin, a natural anticancer compound, alone and in combination with an ATR inhibitor (VE-822), on sensitizing 5-FU-resistant colorectal cancer cells and to elucidate the molecular mechanisms involved in this process. METHODS: In this in vitro study, human colorectal cancer cell line Caco-2 and a 5-FU-resistant line (Caco-2/5-FU) were used. Cell viability and proliferation were assessed by MTT and trypan blue assays, and the ability of long-term cell proliferation was examined by colony formation assay. The expression of genes associated with drug resistance (MDR1/P-gp, ABCG2, ABCC1, YB-1), DNA damage response pathway (ATR, CHK1, H2AX) and apoptosis (Bax, Bcl-2, Caspase-3, PARP-1) was measured by qRT-PCR. The level of DNA damage was assessed by examining the γ-H2AX protein with Western blot. The function of the P-gp pump was measured by the rhodamine 123 accumulation assay and the level of apoptosis was measured by the DNA fragment detection ELISA kit. The cells were treated with diosgenin, VE-822, 5-FU and their double and triple combinations. RESULTS: The results showed that the IC50 of 5-FU in resistant Caco-2/5-FU cells was significantly higher than in sensitive cells, indicating the development of a drug resistance phenotype. Diosgenin alone was able to significantly reduce the viability of both sensitive and resistant cells, although resistant cells showed a lower response. Inhibition of ATR with VE-822 significantly reduced cell viability, and the combination of diosgenin with VE-822 in the presence of 5-FU produced a stronger combined effect and significantly reduced the IC50. Trypan blue and colony formation assays showed a severe reduction in cell survival and long-term proliferation in the combination treatment. Molecularly, the combination treatment significantly inhibited the expression and function of P-gp and reduced the expression of MDR1, ABCG2, ABCC1 and YB-1 genes. The expression of ATR and CHK1, as well as γ-H2AX protein expression levels was also significantly reduced. The Bax/Bcl-2 ratio was increased, and the expression of Caspase-3 and PARP-1 was significantly increased. ELISA results also confirmed a significant increase in apoptosis, especially in the triple treatment of diosgenin+VE-822+5-FU. CONCLUSION: The findings of this study suggest that diosgenin may contribute to reducing 5-FU resistance by affecting ATR/CHK1-associated DNA damage response mechanisms, weakening DNA repair mechanisms, and suppressing drug efflux pumps. The combination of diosgenin with an ATR inhibitor may have a strong combined effect in inducing DNA damage, inhibiting drug resistance, and promoting apoptosis-associated molecular changes. This combination approach may represent a potential chemosensitizing approach for further investigation in colorectal cancer; however, additional validation in diverse models and in vivo studies is required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Solid Tumor Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran.
- Solid Tumor Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran. Electronic address: majidinia.m@umsu.ac.ir.
Förderung
- Urmia University of Medical Sciences
Zitieren
APA
Azizzadeh, B., Mihanfar, A., & Majidinia, M. (2026). Diosgenin enhances 5-fluorouracil sensitivity in drug-resistant colorectal cancer cells via inhibition of ATR/Chk1-mediated DNA damage response. Cancer Treatment and Research Communications, 49, 101426. https://doi.org/10.1016/j.ctarc.2026.101426
Vancouver
Azizzadeh B, Mihanfar A, Majidinia M. Diosgenin enhances 5-fluorouracil sensitivity in drug-resistant colorectal cancer cells via inhibition of ATR/Chk1-mediated DNA damage response. Cancer Treatment and Research Communications. 2026;49:101426. doi:10.1016/j.ctarc.2026.101426
BibTeX
@article{Azizzadeh2026,
author = {Azizzadeh, Bita and Mihanfar, Ainaz and Majidinia, Maryam},
title = {Diosgenin enhances 5-fluorouracil sensitivity in drug-resistant colorectal cancer cells via inhibition of ATR/Chk1-mediated DNA damage response},
journal = {Cancer Treatment and Research Communications},
year = {2026},
volume = {49},
pages = {101426},
doi = {10.1016/j.ctarc.2026.101426}
}
EUVIMED